Maiko Abumiya
Hiroomote, 0108543, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Preventive Effects of Non-sedating and Sedating Histamine H1 Receptor Antagonists Premedication for Subcutaneous Daratumumab-Associated Infusion-Related Reactions: A Prospective Observational Study.
Journal: Biological & pharmaceutical bulletin
Published: July 30, 2026
Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis.
Journal: Cancer chemotherapy and pharmacology
Published: May 04, 2026
Therapeutic drug monitoring guides personalized ponatinib dose reduction for chronic myeloid leukemia.
Journal: International journal of hematology
Published: April 12, 2026
Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia.
Journal: International journal of hematology
Published: December 14, 2024
Bosutinib for Successful Treatment-Free Remission in Chronic Myeloid Leukemia.
Journal: Cancer medicine
Published: December 05, 2024
Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients.
Journal: British journal of clinical pharmacology
Published: October 27, 2022
Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy.
Journal: Cancer chemotherapy and pharmacology
Published: December 08, 2021
Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.
Journal: Scientific reports
Published: October 20, 2020
Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia.
Journal: Journal of clinical pharmacy and therapeutics
Published: July 21, 2020
Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance.
Journal: Journal of clinical pharmacy and therapeutics
Published: July 18, 2020
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
Journal: International journal of hematology
Published: July 12, 2020
Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma.
Journal: Medical oncology (Northwood, London, England)
Published: February 06, 2019
Last Updated: 09/26/2026